{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:49:58Z","timestamp":1794962998653,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Ceftriaxone is commonly used in pediatric infections, but its association with cholelithiasis poses potential health concerns. To determine the pooled frequency of ceftriaxone-induced cholelithiasis in pediatric patients and identify factors commonly associated with its occurrence. Web of Science, PubMed, Google Scholar, and Scopus were systematically searched until March 2024.Studies reporting ceftriaxone-induced cholelithiasis in pediatric patients (0\u201318 years) were included. Randomized controlled trials (RCTs) and prospective and retrospective cohort studies published in English were eligible. PRISMA guidelines were followed. The Newcastle\u2012Ottawa Scale and CASP tools were used to assess risk of bias. A random-effects meta-analysis estimated the pooled frequency. Sensitivity analysis was conducted to explore heterogeneity. The primary outcome was the pooled frequency of ceftriaxone-induced cholelithiasis. Secondary outcomes included identification of factors commonly associated with its occurrence and their impact on symptom burden. Eleven studies (1 RCT, 10 cohort studies) met the inclusion criteria. The pooled frequency of cholelithiasis was 15% (95% CI: 9-23%), with significant heterogeneity (I\u00b2 = 81.76%). Commonly associated factors included high ceftriaxone doses (&gt;\u20092\u00a0g\/day), prolonged use (&gt;\u20095 days), short bolus injections, and dehydration. Most cases resolved upon discontinuation, but symptomatic patients experienced nausea, vomiting, and abdominal pain. Ceftriaxone-induced cholelithiasis is relatively common in pediatric patients, particularly those with associated risk factors. Clinicians should monitor for biliary complications and consider alternative treatments when feasible.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration<\/jats:title>\n            <jats:p>CRD42024503807.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13052-025-02057-w","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:00:27Z","timestamp":1760086827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ceftriaxone-induced cholelithiasis in pediatrics: pooled frequency, symptoms, and associated factors \u2014 systematic review and meta-analysis"],"prefix":"10.1186","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4239-623X","authenticated-orcid":false,"given":"Tahneem","family":"Yaseen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-707X","authenticated-orcid":false,"given":"Khurshid","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Zawiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-6301","authenticated-orcid":false,"given":"Amal K.","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer Hayat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"7","key":"2057_CR1","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","volume":"53","author":"JS Bradley","year":"2011","unstructured":"Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, St Peter SD. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53(7):e25\u201376.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2057_CR2","doi-asserted-by":"publisher","first-page":"e016273","DOI":"10.1136\/bmjopen-2017-016273","volume":"7","author":"L Zeng","year":"2017","unstructured":"Zeng L, Choonara I, Zhang L, Xue S, Chen Z, He M. Safety of ceftriaxone in paediatrics: a systematic review protocol. BMJ Open. 2017;7(8):e016273.","journal-title":"BMJ Open"},{"issue":"4","key":"2057_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000239361","volume":"41","author":"PJ Van Reempts","year":"1995","unstructured":"Van Reempts PJ, Van Overmeire B, Mahieu LM, Vanacker KJ. Clinical experience with ceftriaxone treatment in the neonate. Chemotherapy. 1995;41(4):316\u201322.","journal-title":"Chemotherapy"},{"key":"2057_CR4","doi-asserted-by":"crossref","unstructured":"Azarkar G, Birjand MM, Ehsanbakhsh A, Bijari B, Abedini MR, Ziaee M. Ceftriaxone-associated nephrolithiasis and gallstone in adults. Drug, healthcare and patient safety. 2018;103\u20138.","DOI":"10.2147\/DHPS.S183892"},{"issue":"6","key":"2057_CR5","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/0016-5085(91)90667-A","volume":"100","author":"HZ Park","year":"1991","unstructured":"Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge: identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100(6):1665\u201370.","journal-title":"Gastroenterology"},{"issue":"4","key":"2057_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/(SICI)1097-0096(200005)28:4<166::AID-JCU2>3.0.CO;2-G","volume":"28","author":"A Palanduz","year":"2000","unstructured":"Palanduz A, Yal\u00e7in I, Tongu\u00e7 E, G\u00fcler N, One\u015f U, Salman N, Somer A. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2000;28(4):166\u20138.","journal-title":"J Clin Ultrasound"},{"issue":"4","key":"2057_CR7","first-page":"404","volume":"49","author":"A Soysal","year":"2007","unstructured":"Soysal A, Erasov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. Turk J Pediatr. 2007;49(4):404\u20137.","journal-title":"Turk J Pediatr"},{"issue":"3","key":"2057_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/cpt.176","volume":"98","author":"KL Brouwer","year":"2015","unstructured":"Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, et al. Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther. 2015;98(3):266\u201387.","journal-title":"Clin Pharmacol Ther"},{"key":"2057_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1023\/B:PHAM.0000026420.79421.8f","volume":"21","author":"P Chandra","year":"2004","unstructured":"Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res. 2004;21:719\u201335.","journal-title":"Pharm Res"},{"key":"2057_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","volume":"447","author":"B Hagenbuch","year":"2004","unstructured":"Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP\/SLC21 family: phylogenetic classification as OATP\/SLCO superfamily, new nomenclature and molecular\/functional properties. Pfl\u00fcgers Archiv. 2004;447:653\u201365.","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"8","key":"2057_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1124\/dmd.114.056929","volume":"42","author":"MG Mooij","year":"2014","unstructured":"Mooij MG, Schwarz UI, De Koning BA, Leeder JS, Gaedigk R, Samsom JN, et al. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos. 2014;42(8):1268\u201374.","journal-title":"Drug Metab Dispos"},{"key":"2057_CR12","unstructured":"Tang L, Hines R, Schuetz E, Meibohm B, editors. Age-associated protein expression of pglycoprotein (MDR1\/P-GP) and MRP2 in human pediatric liver. CLINICAL PHARMACOLOGY & THERAPEUTICS; 2007: NATURE PUBLISHING GROUP 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013\u2009\u2013\u20091917 USA."},{"key":"2057_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"2057_CR14","unstructured":"Wells GA SB, O\u2019Connell D et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. May 3, 2021 [Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm"},{"key":"2057_CR15","unstructured":"(CASP) CASP. CASP Randomized Controlled Trial Checklist 2021 [Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/randomised-controlled-trial-rct-checklist\/"},{"issue":"4","key":"2057_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/jpm13040671","volume":"13","author":"A Louta","year":"2023","unstructured":"Louta A, Kanellopoulou A, Alexopoulou Prounia L, Filippas M, Tsami FF, Vlachodimitropoulos A, Vezakis A, Polydorou A, Georgopoulos I, Gkentzi D, Spyridakis I, Karatza A, Sinopidis X. Ceftriaxone administration associated with lithiasis in children: guilty or not?? A systematic review. J Pers Med. 2023;13(4):671. https:\/\/doi.org\/10.3390\/jpm13040671. PMID: 37109057; PMCID: PMC10142585.","journal-title":"J Pers Med"},{"key":"2057_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","volume":"28","author":"R DerSimonian","year":"2007","unstructured":"DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105\u201314.","journal-title":"Contemp Clin Trials"},{"key":"2057_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"2057_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s41182-019-0165-6","volume":"47","author":"GM Tawfik","year":"2019","unstructured":"Tawfik GM, Dila KAS, Mohamed MYF, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47:46. https:\/\/doi.org\/10.1186\/s41182-019-0165-6.","journal-title":"Trop Med Health"},{"key":"2057_CR20","volume-title":"Release 18. College station","author":"SSE StataCorp","year":"2023","unstructured":"StataCorp SSE. Release 18. College station. Volume 18. TX: StataCorp LLC; 2023."},{"issue":"5","key":"2057_CR21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ped.12625","volume":"57","author":"S Murata","year":"2015","unstructured":"Murata S, Aomatsu T, Yoden A, Tamai H. Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis. Pediatr Int. 2015;57(5):942\u20136.","journal-title":"Pediatr Int"},{"issue":"3","key":"2057_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1328-0867.2004.01884.x","volume":"46","author":"O Bor","year":"2004","unstructured":"Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int. 2004;46(3):322\u20134.","journal-title":"Pediatr Int"},{"issue":"6","key":"2057_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0960327116658108","volume":"36","author":"L Ustyol","year":"2017","unstructured":"Ustyol L, Bulut MD, Agengin K, Bala KA, Yavuz A, Bora A, et al. Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: A prospective study in 154 children. Hum Exp Toxicol. 2017;36(6):547\u201353.","journal-title":"Hum Exp Toxicol"},{"key":"2057_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00383-014-3477-y","volume":"30","author":"H Alemayehu","year":"2014","unstructured":"Alemayehu H, Desai AA, Thomas P, Sharp SW. St. Peter SD. Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis. Pediatr Surg Int. 2014;30:323\u20136.","journal-title":"Pediatr Surg Int"},{"issue":"1","key":"2057_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/02841850510015983","volume":"46","author":"A Ozturk","year":"2005","unstructured":"Ozturk A, Kaya M, Zeyrek D, Ozturk E, Kat N, Ziylan S. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol. 2005;46(1):112\u20136.","journal-title":"Acta Radiol"},{"issue":"6","key":"2057_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1055\/s-2008-1072393","volume":"10","author":"JP Bonnet","year":"2000","unstructured":"Bonnet JP, Abid L, Dabhar A, L\u00e9vy A, Soulier Y, Blangy S. Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children:: A prospective study in 34 children. Eur J Pediatr Surg. 2000;10(6):368\u201371.","journal-title":"Eur J Pediatr Surg"},{"issue":"3","key":"2057_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijantimicag.2004.10.008","volume":"25","author":"C Ceran","year":"2005","unstructured":"Ceran C, Oztoprak I, Cankorkmaz L, Gumu\u015f C, Yildiz T, Koyluoglu G. Ceftriaxone-associated biliary pseudolithiasis in pediatric surgical patients. Int J Antimicrob Agents. 2005;25(3):256\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2057_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1179\/027249304225013349","volume":"24","author":"C Acun","year":"2004","unstructured":"Acun C, Erdem LO, S\u00f6\u011f\u00fct A, Erdem CZ, Toma\u00e7 N, G\u00fcndo\u011fdu S, \u00c7avuldak \u015e. Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study. Annals Trop Pediatr. 2004;24(1):25\u201331.","journal-title":"Annals Trop Pediatr"},{"issue":"8625","key":"2057_CR29","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S0140-6736(88)90596-X","volume":"332","author":"U Schaad","year":"1988","unstructured":"Schaad U, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone- associated biliary pseudolithiasis in children. Lancet. 1988;332(8625):1411\u20133.","journal-title":"Lancet"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-02057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-02057-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-02057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:00:30Z","timestamp":1760086830000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-02057-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-02057-w","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval and patient consent required as this study does not involve any patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the participating authors give consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"284"}}